Quidel identifies, develops, manufactures and markets unique diagnostic and research assays and reagents with applications in oncology, bone health and inflammatory diseases. Our kits and reagents are marketed worldwide under the MicroVue brand.

On March 18, 2016, Diagnostic Hybrids, Inc., a wholly-owned subsidiary of Quidel, acquired Immutopics, Inc. (“Immutopics”).  Immutopics, a San Clemente, California-based company, has been in business since 1989 and specializes in innovative assays for assessing bone health.  We are excited about this acquisition and feel that the combination of the complimentary MicroVue™ and Immutopics portfolios will help us better serve the bone health research community.